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Background, Objectives/Goal, Methods/Design, Results, Conclusions limited to 500 words
Background: Naltrexone (NTX), an opioid antagonist metabolized by AKR1C4, is used in pediatrics to treat
numerous conditions involving compulsiveness (e.g., autism spectrum, Prader-Willi, eating disorders, non-suicidal
self-injury). Pharmacokinetic variability is apparent in adults, but no data are present in children.
Objectives/Goal: The purpose of this study was to determine the impact of age and other variables on naltrexone
biotransformation.
Methods/Design: Human liver cytosol samples (n=164) isolated from pediatric and adult donors were treated
with therapeutically relevant concentrations of NTX (0.1, 1 µM). NTX biotransformation was determined by UPLCMS/MS quantification of primary metabolite, 6-beta-naltrexol (6bn), and 6bn formation rate (pmol/mg
protein/min) was calculated. Transcript expression of AKR1C1/2/4 was detected by RNA-seq (n=52). The presence
of non-synonymous AKR1C4 coding region single nucleotide variants (SNPs) was determined by Taq-Man
genotype assays (n=164). Other factors assessed included donor age and sex. Regression analysis was employed.
Results: Human liver donors (n=164), age range 0-79 y (mean 16.0±18.2 y), 37% (n=60) female, 20% (n=33)
heterozygous and 1.2% (n=2) homozygous for co-occurring AKR1C4 variants (S145C/L311V) demonstrated >200fold range in 6bn formation (0.37-76.5 pmol/mg protein/min at NTX 1 µM). Activity increased steadily from birth
reaching a peak in middle childhood (6-11 years) followed by a decline through adulthood to 54% of the peak
activity in those aged 22-50 years. AKR1C4 expression explained 31% of the variability in 6bn formation (p<0.01).
A multiple regression model including AKR1C4 expression, S145C/L311V, age, ethnicity, and cytosol protein per

gram liver-CPPGL explained 65% of variability in 6bn formation (p<0.001). Sex did not have a significant impact on
6bn formation.
Conclusions: NTX biotransformation is highly variable in pediatric and adult liver samples and able to be
explained by individual factors, most of which are feasible to obtain (e.g., genotype, age and ethnicity). This data
may inform a precision therapeutics approach (e.g., exposure optimization) to further study NTX responsiveness
in children.

